Q2 Earnings Estimate for HRTX Issued By Northland Capmk

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Stock analysts at Northland Capmk issued their Q2 2025 earnings estimates for Heron Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Northland Capmk analyst C. Byrnes anticipates that the biotechnology company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics' FY2025 earnings at $0.01 EPS.

HRTX has been the subject of several other reports. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX traded down $0.06 during mid-day trading on Thursday, hitting $2.11. The company had a trading volume of 1,708,734 shares, compared to its average volume of 2,320,733. Heron Therapeutics has a one year low of $1.04 and a one year high of $3.93. The firm has a fifty day moving average price of $2.19 and a 200 day moving average price of $1.82. The company has a market capitalization of $321.91 million, a PE ratio of -11.72 and a beta of 1.33.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million.

Institutional Trading of Heron Therapeutics

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Heron Therapeutics by 0.8% during the first quarter. Vanguard Group Inc. now owns 8,225,585 shares of the biotechnology company's stock worth $18,096,000 after buying an additional 67,976 shares during the last quarter. Palisade Capital Management LP lifted its position in Heron Therapeutics by 34.7% in the 1st quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock valued at $11,631,000 after acquiring an additional 1,360,542 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Heron Therapeutics during the 4th quarter valued at about $4,706,000. AIGH Capital Management LLC bought a new stake in Heron Therapeutics during the 1st quarter worth approximately $6,112,000. Finally, Congress Park Capital LLC raised its stake in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.